Viadur (Leuprolide Acetate) - Summary

VIADUR SUMMARY

Viadur® (leuprolide acetate implant) is a sterile nonbiodegradable, osmotically driven miniaturized implant designed to deliver leuprolide acetate for 12 months at a controlled rate (Figure A). Viadur® incorporates DUROS® technology. The system contains 65 mg of leuprolide (free base). Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH or LH-RH). The analog possesses greater potency than the natural hormone. The implant is inserted subcutaneously in the inner aspect of the upper arm. After 12 months, the implant must be removed. At the time an implant is removed, another implant may be inserted to continue therapy.

Viadur® is indicated in the palliative treatment of advanced prostate cancer.

VIADUR NEWS HIGHLIGHTS

Published Studies Related to Viadur (Leuprolide)

Tibolone reverses the cognitive effects caused by leuprolide acetate administration, improving mood and quality of life in patients with symptomatic uterine leiomyomas. [2008.07]

Tibolone reverses the cognitive effects caused by leuprolide acetate administration, improving mood and quality of life in patients with symptomatic uterine leiomyomas. [2007.11.12]

Impact of leuprolide acetate on luteal phase function in women undergoing controlled ovarian hyperstimulation and intrauterine insemination. [2006.02]

Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. [2006.02]

Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. [2006.01]

more>>

Clinical Trials Related to Viadur (Leuprolide)

Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy [Active, not recruiting]

A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer [Completed]

Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF [Completed]

Study of Lupron Depot In The Treatment of Central Precocious Puberty [Active, not recruiting]

Melanoma Vaccine With Peptides and Leuprolide [Recruiting]

more>>